About ImmunoGen
ImmunoGen is a company based in Waltham (United States) founded in 1981 was acquired by AbbVie in November 2023. ImmunoGen has raised $126 million across 5 funding rounds from investors including AbbVie. The company has 106 employees as of December 31, 2022. ImmunoGen operates in a competitive market with competitors including Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
- Headquarter Waltham, United States
- Employees 106 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
$108.78 M (USD)56as on Dec 31, 2022
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$126 M (USD)
in 5 rounds
-
Latest Funding Round
$100 M (USD), Private Equity Round
Jun 01, 2016
- Investors
-
Employee Count
106
as on Dec 31, 2022
-
Acquired by
AbbVie
(Nov 30, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of ImmunoGen
Unlock access to complete
Unlock access to complete
Funding Insights of ImmunoGen
ImmunoGen has successfully raised a total of $126M across 5 strategic funding rounds. The most recent funding activity was a Private Equity Round of $100 million completed in June 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ImmunoGen
ImmunoGen has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include AbbVie.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
Locked | Locked | Locked |
Investor details for ImmunoGen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ImmunoGen
Investment portfolio details for ImmunoGen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ImmunoGen
Detailed financials for ImmunoGen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Immunogen Comparisons
Peer comparison for ImmunoGen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ImmunoGen
ImmunoGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| Locked | Locked | Locked |
Targeted therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of ImmunoGen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Immunogen
Complete news archive for ImmunoGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ImmunoGen
ImmunoGen was founded in 1981 and raised its 1st funding round 30 years after it was founded.
ImmunoGen is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Mark Enyedy is the current CEO of ImmunoGen.
ImmunoGen is a funded company, having raised a total of $126M across 5 funding rounds to date.
As of Dec 31, 2022, the latest employee count at ImmunoGen is 106.
Annual revenue of ImmunoGen is $108.78M as on Dec 31, 2022.
ImmunoGen was founded in 1981 and is headquartered in Waltham, United States. Targeted anticancer therapeutics are developed using proprietary antibody-drug conjugate technology within the biotechnology sector. Operations focus on creating treatments for solid tumors, including the lead candidate Mirvetuximab Soravtansine for folate receptor α-positive ovarian cancers. The technology is incorporated into Roches Kadcyla for HER2-positive metastatic breast cancer and is licensed to various healthcare companies for further applications.
ImmunoGen's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Syndax.
ImmunoGen has 1 investor. Key investors include AbbVie.